EMJ Oncology 8 [Supplement 3] . 2020

In this issue

Patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) derive little benefit from standard therapies and have an extremely poor prognosis. Recent data has demonstrated that adding an anti-epidermal growth factor receptor (EGFR) agent to a BRAF inhibitor, with or without an MEK inhibitor, improves overall survival and response rates compared to irinotecan-based chemotherapy for these patients.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.